Edition:
Deutschland

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,528JPY
06:50 Uhr
Change (% chg)

¥18 (+1.23%)
Prev Close
¥1,509
Open
¥1,514
Day's High
¥1,528
Day's Low
¥1,509
Volume
4,526,400
Avg. Vol
7,671,028
52-wk High
¥1,570
52-wk Low
¥1,332

4503.T

Chart for 4503.T

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive... (more)

Buy/Sell

Sell Hold Buy
2.83 Mean rating from 12 analysts

Overall

Beta: 0.60
Market Cap(Mil.): ¥3,012,207.00
Shares Outstanding(Mil.): 2,068.82
Dividend: 18.00
Yield (%): 2.34

Nikkei rises on relief over Kuroda's BOJ reappointment

TOKYO, Feb 16 Japanese stocks rose on Friday morning, with investors relieved to see the government appoint Bank of Japan Governor Haruhiko Kuroda for another term and choose an advocate of bolder monetary easing as one of his deputies.

BRIEF-Astellas Pharma acquires Universal Cells

* Says it has acquired Universal Cells Inc., and will pay up to $102.5 million of upfront and milestones to acquire 100 percent ownership of Universal Cells depending on achievement of certain specified clinical milestones

BRIEF-Astellas acquires Universal Cells Inc

* ASTELLAS WILL PAY UP TO $102.5 MILLION OF UPFRONT AND MILESTONES TO ACQUIRE 100 PERCENT OWNERSHIP OF UNIVERSAL CELLS

BRIEF-Astellas Pharma says top-line results for two phase 3 trials of Peficitinib in rheumatoid arthritis patients

* Says it announced that the results of two phase 3 trials (RAJ3 and RAJ4 trials) on Peficitinib hydrobromide, an oral JAK inhibitor developed by the co, in rheumatoid arthritis patients with an inadequate response to existing therapy, demonstrated superiority over placebo regarding the two trials' primary endpoints

CORRECTED-Nikkei ekes out small gains, investors wary as U.S. futures fall

TOKYO, Feb 7 Japanese stocks pared early gains to end a notch higher in volatile trade on Wednesday, as investors stayed on guard for more losses in global equity markets after U.S. futures slipped.

Nikkei rises as Wall St rebounds after bruising sell-off; Toyota jumps

TOKYO, Feb 7 Japanese stocks bounced sharply on Wednesday morning after crumbling to their biggest percentage fall in 15 months the previous day, with all sectors in the black as Wall Street pulled ahead following a punishing sell-off in the preceding days.

Pfizer's Xtandi delays prostate cancer spread in early stage disease

Feb 5 Use of Xtandi in early stage prostate cancer on top of standard hormone therapy reduced the risk of disease spreading or death by 71 percent compared with hormone therapy alone, study results that could lead to significantly increased sales of the Pfizer Inc and Astellas Pharma Inc medicine.

BRIEF-Astellas Pharma says change of chairman and president

* Says it appoints Yoshihiko Hatanaka as new chairman of the board, Kenji Yasukawa as new president and CEO, effective April 1

BRIEF-Astellas Pharma to repurchase up to 2.1 pct shares

* Says it will repurchase up to 42 million shares, representing 2.1 percent of outstanding

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie +0.19%
Rohstoffe +0.15%
Industrie +0.09%
Konjunktur abhängige Waren & Dienstleistungen -0.10%
Konjunktur unabhängige Waren & Dienstleistungen +0.04%
Finanzindustrie -0.01%
Pharma +0.01%
Technologie +0.09%
Telekommunikation +0.09%